Business Overview: Marker Therapeutics, Inc. (NASDAQ: MRKR)

---

Executive Summary

Marker Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing non-genetically-modified, multi-antigen-targeted T-cell therapies for cancer, built on technology exclusively licensed from Baylor College of Medicine (BCM). Unlike CAR-T therapies, Marker's MAR-T (Multi Antigen Recognizing T-cell) platform expands a patient's or donor's own naturally-occurring tumor-specific T cells — engineered to recognize up to six tumor-associated antigens simultaneously — without genetic modification, an approach the company argues reduces the risk of tumors "escaping" treatment by mutating away from a single targeted antigen.

Marker has no approved products and ended 2025 with roughly $17 million in cash, with management guiding runway through the fourth quarter of 2026 (later extended via subsequent financing, per 2026 updates). Its lead program, MT-601, has shown encouraging early response rates in lymphoma patients who relapsed after CAR-T therapy — a population with few remaining options.

---

1. Core Business Model & How They Work

Marker's business model is standard clinical-stage biotech: advance its licensed cell-therapy platform through trials funded by a mix of equity capital, non-dilutive government/foundation grants, and eventually partnership or acquisition value, with the goal of reaching pivotal data that attracts a larger partner or supports its own path to approval.

[ License BCM T-Cell Technology ] ➡️ [ Manufacture Multi-Antigen T Cells (Autologous or Off-the-Shelf) ] ➡️ [ Phase 1/2 Clinical Trials ] ➡️ [ Pivotal Data / Partnership or Approval Path ] ➡️ [ Commercialization (Partner-Led or Direct) ]

A distinctive feature of Marker's model is its off-the-shelf (OTS) manufacturing ambition: unlike many autologous (patient-specific) cell therapies, Marker's MT-401-OTS program is designed so that a single healthy donor's cell material could treat approximately 40 patients, which — if validated — would meaningfully lower per-patient manufacturing cost and complexity relative to bespoke autologous CAR-T products.

---

2. Business Segments

Marker operates as a single clinical-stage biopharmaceutical business; there are no reportable segments. Its pipeline spans three programs built on the same underlying MAR-T platform:

┌───────────────────────────────────────────────────────────────────┐
│                     Marker Therapeutics Pipeline                      │
├───────────────────┬────────────────────────┬────────────────────────┤
│ MT-601 (Lymphoma)   │ MT-601 (Pancreatic)      │ MT-401-OTS (AML/MDS)   │
│ Phase 1 APOLLO,      │ Phase 1 PANACEA          │ Phase 1 RAPID,          │
│ CAR-T-relapsed/      │ (+ chemo), orphan        │ off-the-shelf donor    │
│ -ineligible DLBCL    │ drug designation          │ product                 │
└───────────────────────┴──────────────────────────┴────────────────────────┘

---

3. Product Portfolio

---

4. Competitive Landscape

• CD19-directed CAR-T therapies (lymphoma): Four approved products compete in the relapsed lymphoma space, but up to 60% of treated patients eventually relapse — the exact population MT-601 targets as a post-CAR-T option.
• Other cell/antibody approaches: Non-CD19 and multi-target CAR-T programs, NK-CAR therapies, and bispecific antibodies (from large players such as Gilead/Kite, Bristol Myers Squibb, Novartis, and Johnson & Johnson/Legend Biotech) all compete for the same relapsed/refractory lymphoma and leukemia patient populations, generally with far greater financial resources than Marker.
• Differentiation: Marker states that MT-601 is, to its knowledge, the only natural (non-gene-modified) multi-antigen T-cell product being explored specifically in CAR-T-relapsed lymphoma — a narrower, less-contested niche than head-on CAR-T competition.

---

5. Strategic Strengths & Risks

Strengths (the moat): Marker's exclusive worldwide license from Baylor College of Medicine (signed 2018) gives it sole rights to a multi-antigen T-cell platform validated across several earlier academic trials in lymphoma, pancreatic cancer, and post-transplant AML/MDS. Its focus on the CAR-T-relapsed population — patients with few remaining treatment options — is a differentiated niche rather than head-to-head CAR-T competition, and non-dilutive grant funding from CPRIT (up to $22.6 million combined across two programs) and the NIH SBIR program has helped offset capital intensity.

Risks: Marker has no approved products and a limited cash runway (guided through Q4 2026 as of its FY2025 10-K, before any subsequent financing), meaning continued dilutive fundraising or a partnership is likely necessary to reach pivotal data. All clinical results to date are from small, early-stage trials (24 patients in the key APOLLO readout), and the company's CPRIT grants carry revenue-sharing obligations (capped at 400% of funds received) that would reduce Marker's eventual economics if a program succeeds commercially. The March 2025 termination of its Cell Ready manufacturing agreement (tied to a former director) also underscores manufacturing-partner execution risk as it scales toward off-the-shelf production.

---

6. Financial Overview

---

7. Summary Conclusion

Marker Therapeutics is a focused, small-cap clinical-stage biotech betting on a differentiated, non-gene-modified, multi-antigen T-cell platform licensed from Baylor College of Medicine, with its clearest near-term opportunity in the underserved population of lymphoma patients who have relapsed after CAR-T therapy. Early MT-601 response-rate data is genuinely encouraging for such a difficult-to-treat population, and non-dilutive grant funding has helped stretch the company's limited cash. The central question is one of funding runway and execution: with only roughly a year of cash visibility as of its FY2025 filing, Marker's ability to generate the kind of pivotal data that attracts a larger partner — before needing further dilutive capital — will determine whether its differentiated science translates into commercial value.